{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T02:22:41Z","timestamp":1789525361186,"version":"build-2803163510"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T00:00:00Z","timestamp":1706832000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002322","name":"CAPES","doi-asserted-by":"publisher","award":["PROEX 0730\/2020"],"award-info":[{"award-number":["PROEX 0730\/2020"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004263","name":"FAPERGS","doi-asserted-by":"publisher","award":["ARD 04\/2019"],"award-info":[{"award-number":["ARD 04\/2019"]}],"id":[{"id":"10.13039\/501100004263","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004263","name":"FAPERGS","doi-asserted-by":"publisher","award":["19\/2551-0001321-3"],"award-info":[{"award-number":["19\/2551-0001321-3"]}],"id":[{"id":"10.13039\/501100004263","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.jgar.2024.02.001","type":"journal-article","created":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T12:30:08Z","timestamp":1707481808000},"page":"393-398","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Evaluation of clinical and microbiological factors related to mortality in patients with Gram-negative bacterial infections treated with ceftazidime\u2013avibactam: A prospective multicentric cohort study"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4464-9763","authenticated-orcid":false,"given":"Beatriz","family":"Arns","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8129-4853","authenticated-orcid":false,"given":"Guilherme Geraldo Lovato","family":"Sorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarsila","family":"Vieceli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9119-6242","authenticated-orcid":false,"given":"Dariane","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8947-8005","authenticated-orcid":false,"given":"\u00c2ndrea","family":"Celestino de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscila","family":"Lamb Wink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia Hoefel","family":"Paes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda","family":"Barboza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9509-134X","authenticated-orcid":false,"given":"Stella","family":"Hickmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ant\u00f4nio C\u00e2ndido","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anelise","family":"da Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelle","family":"Duarte Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cibele","family":"Massotti Magagnin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre Prehn","family":"Zavascki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9465-2613","authenticated-orcid":false,"given":"Maria Helena","family":"Rigatto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2024.02.001_bib0001","unstructured":"Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug-resistant bacterial infections, including tuberculosis. Geneva: World Health Organization; 2017 https:\/\/www.who.int\/publications\/i\/item\/WHO-EMP-IAU-2017.12, Accessed 27 February 2024."},{"key":"10.1016\/j.jgar.2024.02.001_bib0002","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1001\/jama.2016.11764","article-title":"Antimicrobial resistance","volume":"316","author":"Marston","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jgar.2024.02.001_bib0003","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1586\/eri.13.4","article-title":"Impact of antimicrobial multidrug resistance on inpatient care cost: an evaluation of the evidence","volume":"11","author":"Tansarli","year":"2013","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.jgar.2024.02.001_bib0004","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ijantimicag.2018.07.004","article-title":"Evaluation of the efficacy and safety of ceftazidime\/avibactam in the treatment of gram-negative bacterial infections: a systematic review and meta-analysis","volume":"52","author":"Zhong","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2024.02.001_bib0005","article-title":"Efficacy and safety of ceftazidime-avibactam for the treatment of carbapenem-resistant enterobacterales bloodstream infection: a systematic review and meta-analysis","volume":"10","author":"Chen","year":"2022","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.jgar.2024.02.001_bib0006","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/bcp.15586","article-title":"Clinical efficacy of renal dosing adjustments of ceftazidime-avibactam in patients affected by carbapenem-resistant gram-negative infections: a systematic review and meta-analysis of observational studies","volume":"89","author":"Gatti","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jgar.2024.02.001_bib0007","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02647-22","article-title":"Risk factors for carbapenem-resistant Enterobacterales clinical treatment failure","volume":"11","author":"Rebold","year":"2023","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.jgar.2024.02.001_bib0008","doi-asserted-by":"crossref","first-page":"e02497","DOI":"10.1128\/AAC.02497-17","article-title":"Pneumonia and renal replacement therapy are risk factors for ceftazidime-avibactam treatment failures and resistance among patients with carbapenem-resistant Enterobacteriaceae infections","volume":"62","author":"Shields","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.02.001_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106075","article-title":"Ceftazidime-avibactam in the treatment of infections caused by KPC-producing Klebsiella pneumoniae: factors associated with clinical efficacy in a single-center cohort","volume":"56","author":"Cast\u00f3n","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2024.02.001_bib0010","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"10.1016\/j.jgar.2024.02.001_bib0011","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1097\/00003246-198510000-00009","article-title":"APACHE II: a severity of disease classification system","volume":"13","author":"Knaus","year":"1985","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jgar.2024.02.001_bib0012","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST) Clinical breakpoints and dosing of antibiotics. www.eucast.org\/clinical_breakpoints\/. Accessed 24 March 2022."},{"key":"10.1016\/j.jgar.2024.02.001_bib0013","series-title":"PASW statistics for windows","year":"2009"},{"key":"10.1016\/j.jgar.2024.02.001_bib0014","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/cid\/ciy492","article-title":"Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae","volume":"68","author":"Tumbarello","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2024.02.001_bib0015","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/jac\/dkaa503","article-title":"Ceftazidime\/avibactam in the era of carbapenemase-producing Klebsiella pneumoniae: experience from a national registry study","volume":"76","author":"Karaiskos","year":"2021","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.jgar.2024.02.001_bib0016","doi-asserted-by":"crossref","first-page":"e01052","DOI":"10.1128\/AAC.01052-20","article-title":"Is ceftazidime\/avibactam an option for serious infections due to extended-spectrum-\u03b2-lactamase- and AmpC-producing enterobacterales? A systematic review and meta-analysis","volume":"65","author":"Isler","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.02.001_bib0017","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.ijantimicag.2019.02.022","article-title":"Phylogenetic analysis of resistance to ceftazidime\/avibactam, ceftolozane\/tazobactam and carbapenems in piperacillin\/tazobactam-resistant Pseudomonas aeruginosa from cystic fibrosis patients","volume":"53","author":"Zamudio","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2024.02.001_bib0018","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.2147\/IDR.S173804","article-title":"Multidrug-resistant Pseudomonas aeruginosa from sputum of patients with cystic fibrosis demonstrates a high rate of susceptibility to ceftazidime-avibactam","volume":"11","author":"Atkin","year":"2018","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jgar.2024.02.001_bib0019","doi-asserted-by":"crossref","first-page":"e02311","DOI":"10.1128\/AAC.02311-19","article-title":"Ceftazidime-avibactam resistance mediated by the N(346)Y substitution in various AmpC \u03b2-lactamases","volume":"64","author":"Compain","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.02.001_bib0020","first-page":"3336","article-title":"Selection of mutants with resistance or diminished susceptibility to ceftazidime\/avibactam from ESBL- and AmpC-producing Enterobacteriaceae","volume":"73","author":"Livermore","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2024.02.001_bib0021","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1093\/jac\/dkx298","article-title":"AmpC \u03b2-lactamase induction by avibactam and relebactam","volume":"72","author":"Livermore","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2024.02.001_bib0022","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00447-22","article-title":"Klebsiella pneumoniae carbapenemase variants resistant to ceftazidime-avibactam: an evolutionary overview","volume":"66","author":"Hobson","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.02.001_bib0023","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.823626","article-title":"The collateral effects of COVID-19 pandemic on the status of carbapenemase-producing pathogens","volume":"12","author":"Ayoub Moubareck","year":"2022","journal-title":"Front Cell Infect Microbiol"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716524000286?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716524000286?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T10:01:36Z","timestamp":1761991296000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716524000286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":23,"alternative-id":["S2213716524000286"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2024.02.001","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of clinical and microbiological factors related to mortality in patients with Gram-negative bacterial infections treated with ceftazidime\u2013avibactam: A prospective multicentric cohort study","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2024.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}